We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Industry groups have taken aim at an FDA recommendation on creating committees for assessing safety for INDs, saying the agency should adopt a more flexible approach. Read More
The Pharmaceutical Research and Manufacturers Association singled out China and Canada as two of the 20 countries to watch for intellectual property transgressions in 2016. Read More
Buried deep in the administration’s budget proposal are a series of drug price control measures that could rattle the pharmaceutical industry. Read More